Overview

A Safety and Efficacy Study of SHR4640 and Febuxostat in Subjects With Hyperuricemia

Status:
Unknown status
Trial end date:
2020-08-30
Target enrollment:
Participant gender:
Summary
The objective of the study is to assess the Safety and Efficacy of SHR4640 and Febuxostat in patients with Hyperuricemia.
Phase:
Phase 2
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Treatments:
Febuxostat